- Home
- IBRX vs BEP Comparison
IBRX vs BEP Comparison
Compare IBRX & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | BEP |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 5870 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.4B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBRX | BEP |
|---|---|---|
| Price | $7.59 | $32.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $12.57 | ★ $34.70 |
| AVG Volume (30 Days) | ★ 24.1M | 829.4K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.76% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $14.36 |
| Revenue Next Year | $131.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.83 | $19.29 |
| 52 Week High | $12.43 | $32.78 |
Technical Indicators
Market Signals| Indicator | IBRX | BEP |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 63.54 |
| Support Level | $2.25 | $29.65 |
| Resistance Level | $8.28 | N/A |
| Average True Range (ATR) | 0.93 | 1.01 |
| MACD | -0.24 | 0.10 |
| Stochastic Oscillator | 39.00 | 92.96 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.